Filtered By:
Infectious Disease: COVID-19
Drug: Aspirin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 17 results found since Jan 2013.

E-132 Successful mechanical thrombectomy in an 11-year-old patient with emergent large vessel occlusion acute ischemic stroke related to congenital complete heart block and recent covid-19 infection
ConclusionsThis is a first known report of a successful mechanical thrombectomy in a pediatric patient due to a large vessel occlusion related to congenital complete heart block and recent COVID-19 infection.Disclosures J. Ansari: None. D. Mata Canadas: None. M. Ayub: None. J. Caskey: None. P. Simoncini: None. R. Riel-Romero: None. P. Sharma: None. D. Jordan: None. H. Cuellar: None.
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Ansari, J., Mata Canadas, D., Ayub, M., Caskey, J., Simoncini, P., Riel-Romero, R., Sharma, P., Jordan, D., Cuellar, H. Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

COVID-19 Infection and Recurrent Stroke in Young Patients With Protein S Deficiency: A Case Report
Conclusions: SARS-CoV-2 infection potentializes the prothrombotic effect and vascular inflammation by accentuating protein S deficit. The place of steroids seems justifiable in the presence of symptoms of vasculitis in brain imaging.
Source: The Neurologist - November 1, 2021 Category: Neurology Tags: Case Report/Case Series Source Type: research

E-004 Focal intracranial vasculopathy as a manifestation of COVID-19-associated acute ischemic stroke
ConclusionTo our knowledge, our case is the first to illustrate the potential for COVID-19 infection to present as a focal intracranial vasculopathy in an otherwise healthy young-patient, resulting in acute ischemic stroke without an underlying hypercoagulable state. Rescue intracranial stenting was necessary to maintain vessel patency and restore intracranial flow.Disclosures A. Mahapatra: None. A. Witek: None. G. Toth: None.
Source: Journal of NeuroInterventional Surgery - July 26, 2021 Category: Neurosurgery Authors: Mahapatra, A., Witek, A., Toth, G. Tags: Electronic poster abstracts Source Type: research

Dual antiplatelet use in the management of COVID-19 associated acute ischemic stroke reocclusion
CONCLUSION: COVID-19 AIS may be associated with a hypercoagulable state which risks malignant reocclusion complicating MT. We found antithrombotic treatment periprocedural cangrelor with or without argatroban transitioned to oral aspirin with ticagrelor to be a viable method for management of these patients.PMID:35549746 | DOI:10.1177/15910199221097484
Source: Interventional Neuroradiology - May 13, 2022 Category: Radiology Authors: Joshua Feler Carlin Chuck Matthew Anderson Jonathan Poggi Joseph Sweeney Krisztina Moldovan Mahesh V Jayaraman Ryan McTaggart Radmehr Torabi Source Type: research

A case of ischemic stroke and transient thrombocytopenia in a young female following adenoviral vector-based COVID-19 vaccination: Was the association incidental or causal?
We report a 23-year-old healthy female who developed seizures, altered sensorium, and left hemiparesis, 20 days after receiving the first dose of adenoviral vector-based COVID-19 vaccine "Covishield™." The patient had transient thrombocytopenia. The D-dimer level was 2460 ng/mL. Magnetic resonance imaging (MRI) demonstrated occlusion of M2 segment of the middle cerebral artery and cerebral infarction. Platelet factor-4 antibodies level was normal. Treatment with aspirin and antiepileptic drugs resulted in a remarkable recovery. This is the first Indian case report of ischemic stroke and transient thrombocytopenia followi...
Source: Primary Care - January 9, 2023 Category: Primary Care Authors: Shweta Pandey Ravindra Kumar Garg Pooja Tripathi Hardeep S Malhotra Neeraj Kumar Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 Associated Reversible Cerebral Vasoconstriction Syndrome Successfully Treated with Nimodipine and Aspirin
A 31-year-old sexually active, non-smoker female with a past medical history of spina-bifida and idiopathic thoracolumbar scoliosis status post hardware spinal fusion surgery five years ago presented with a one-day history of severe holocranial headaches associated with nausea and visual changes. A thorough neurological examination was intact. She complained of mild cough as well. She had a positive nasopharyngeal swab for SARS-CoV-2 on RT-PCR assay. A comprehensive drug screen including amphetamines, cocaine, nicotine, alcohol, and ecstasy as well as a pregnancy test were negative; coagulation profile was within normal limits.
Source: Journal of Stroke and Cerebrovascular Diseases - April 12, 2021 Category: Neurology Authors: Tarab Mansoor, Ali A. Alsarah, Hossein Mousavi, Javed Elyias, Tarun Girotra, Omar Hussein Tags: Case Report Source Type: research

Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets
Platelets. 2021 Jun 7:1-9. doi: 10.1080/09537104.2021.1936478. Online ahead of print.ABSTRACTPlatelets may be a target of bacteria and viruses, which can directly or indirectly activate them so promoting thrombosis. In accordance with this, community-acquired pneumonia (CAP) is complicated by ischemia-related vascular disease (myocardial infarction and stroke) in roughly 10% of patients while the incidence of venous thrombosis is uncertain. In CAP platelet biosynthesis of TxA2 is augmented and associated with myocardial infarction; however, a cause-effect relationship is still unclear as unclear is if platelet activation p...
Source: Platelets - June 7, 2021 Category: Hematology Authors: Francesco Violi Vittoria Cammisotto Pasquale Pignatelli Source Type: research

Progress in aorta and peripheral cardiovascular disease research
AbstractAlthough coronavirus disease 2019 seems to be the leading topic in research number of outstanding studies have been published in the field of aorta and peripheral vascular diseases likely affecting our clinical practice in the near future. This review article highlights key research on vascular diseases published in 2020. Some studies have shed light in the pathophysiology of aortic aneurysm and dissection suggesting a potential role for kinase inhibitors as new therapeutic options. A first proteogenomic study on fibromuscular dysplasia (FMD) revealed a promising novel disease gene and provided proof-of-concept for...
Source: Cardiovascular Research - April 23, 2021 Category: Cardiology Source Type: research

Antithrombotic Therapy Not Warranted in COVID-19 Outpatients Antithrombotic Therapy Not Warranted in COVID-19 Outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI, stroke, or hospitalization in the ACTIV-4B trial.Medscape Medical News
Source: Medscape Cardiology Headlines - October 20, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research